Neuromod Devices

Neuromod Devices is a Dublin-based Irish MedTech company operating at the forefront of the neuromodulation sector. The company developed Lenire, a CE-marked bimodal neuromodulation device designed to treat chronic tinnitus, a condition affecting hundreds of millions of people worldwide. Lenire works by delivering precisely coordinated stimulation through two simultaneous channels: auditory tones delivered via headphones and mild electrical pulses delivered to the tongue through a proprietary mouthpiece. This combination of sound and somatosensory stimulation is designed to drive neuroplastic changes in the brain, targeting the underlying neural mechanisms of tinnitus rather than simply masking its symptoms.

Neuromod Devices has achieved significant clinical and commercial milestones that distinguish it within the competitive MedTech landscape. Lenire received CE marking, establishing it as the first bimodal neuromodulation device approved for tinnitus treatment in Europe, and the company has backed its technology with robust clinical evidence from large-scale trials. The company has raised $40 million in Series B funding, reflecting strong investor confidence in both the technology and the commercial opportunity ahead. These milestones position Neuromod Devices as a credible and well-resourced player capable of scaling its product across international markets.

Neuromod Devices represents a meaningful advance for the broader neurotech and neuromodulation industry by demonstrating that non-invasive, patient-administered neurostimulation can generate clinically validated outcomes for a historically underserved condition. Tinnitus has long lacked effective therapeutic options, and Lenire's success challenges the conventional boundaries of what neuromodulation can address beyond neurological movement disorders or pain. The company's bimodal approach also signals a growing shift in the field toward multi-sensory stimulation paradigms that engage the brain's plasticity more comprehensively. As the neurotech industry continues to mature, Neuromod Devices serves as an important proof of concept that targeted neuromodulation can be both scientifically rigorous and commercially viable.